Skip to content


IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)

Funds Source:

European Union


01/05/2023 to 30/04/2027

Project typology:

European consortium project

Project status:


Funding Entity:

Comisión Europea (CE)


273,779 €

IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3

The aim of IMMUTOL isthe fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches.

Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products.


Fondazione Telethon ETS

Ospedale San Raffaele SRL

Institut de Investigació en Ciències de la Salut Germans Trias i Pujol

Stichting Sanquin Bloedvoorziening

Universidad de Navarra

Asphalion SL

Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag

Innovation Acta SRL

Asociación de Esclerosis Múltiple de Toledo